

Schrödinger inks strategic collaboration with Thermo Fisher

26 June 2020 | News

Schrödinger will identify drug discovery targets and Thermo Fisher will obtain cryo-EM structures of these targets



US based Schrödinger has announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with *in silico* compound screening to accelerate drug discovery.

The collaboration brings together Schrödinger's physics-based software platform with Thermo Fisher's world-leading cryo-EM technology to expand the applicability of structure-based drug discovery to a wider array of targets which may not be amenable to structure prediction via x-ray crystallography.

Schrödinger will identify drug discovery targets and Thermo Fisher will obtain cryo-EM structures of these targets with bound ligands. Schrödinger will then leverage its advanced computational platform, together with the cryo-EM structures, to identify development candidates.